Sugi Predict

Sugi Predict / Targets / FAM20C

FAM20C

Extracellular serine/threonine protein kinase FAM20C · Q8IXL6 · FAM20C on Sugi Atlas →

230 patent compounds predicted against FAM20C, 188 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6980742 SCHEMBL6980742 0.78 1/20
SCHEMBL6979115 SCHEMBL6979115 0.70 1/20
SCHEMBL1116426 SCHEMBL1116426 0.66 1/20
SCHEMBL1116462 SCHEMBL1116462 0.66 1/20
SCHEMBL1116441 SCHEMBL1116441 0.65 1/20
SCHEMBL6967800 SCHEMBL6967800 0.64 1/20
SCHEMBL31180291 SCHEMBL31180291 0.64 1/20
SCHEMBL6981398 SCHEMBL6981398 0.63 1/20
SCHEMBL6976835 SCHEMBL6976835 0.63 1/20
SCHEMBL6981464 SCHEMBL6981464 0.63 1/20
SCHEMBL6968704 SCHEMBL6968704 0.62 1/20
SCHEMBL6974286 SCHEMBL6974286 0.62 1/20
SCHEMBL6976694 SCHEMBL6976694 0.61 1/20
SCHEMBL6048148 SCHEMBL6048148 0.61 1/20
SCHEMBL1116439 SCHEMBL1116439 0.61 1/20
SCHEMBL6976607 SCHEMBL6976607 0.61 1/20
SCHEMBL6980901 SCHEMBL6980901 0.61 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7955834) 0.61 1/20
SCHEMBL14898950 SCHEMBL14898950 0.61 1/20
SCHEMBL1039693 SCHEMBL1039693 0.59 1/20

Clinical trials — most relevant to FAM20C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC PHASE2NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment nanUNKNOWN
Human Epilepsy Genetics--Neuronal Migration Disorders Study nanRECRUITING
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy. nanCOMPLETED
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Genetic Analysis of Fraser Syndrome and Fryns Syndrome nanCOMPLETED
Mapping Novel Disease Genes for Dilated Cardiomyopathy nanCOMPLETED
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions nanRECRUITING
Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China nanUNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders nanCOMPLETED
Exome Analysis in Hearing Impaired Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FAM20C binder may also engage these)

ProteinNameSimilarity
Q5MJS3 — 0.998 Q5MJS3 →
Q96MK3 — 0.993 Q96MK3 →
A4VCL2 — 0.989 A4VCL2 →
Q8CID3 — 0.988 Q8CID3 →
P86275 — 0.983 P86275 →
Q701R2 — 0.981 Q701R2 →
Q3UPI1 — 0.981 Q3UPI1 →
Q5QQ37 — 0.980 Q5QQ37 →
Q5ZEQ8 — 0.980 Q5ZEQ8 →
Q6P7B4 — 0.979 Q6P7B4 →
Q810K9 — 0.979 Q810K9 →
Q9XTW2 — 0.979 Q9XTW2 →
Q6UWH4 — 0.978 Q6UWH4 →
Q3V1T4 — 0.978 Q3V1T4 →
Q5ZIK0 — 0.978 Q5ZIK0 →
Q8BQT2 — 0.978 Q8BQT2 →
Q0P6D2 — 0.977 Q0P6D2 →
Q8BHP7 — 0.976 Q8BHP7 →
P54360 — 0.976 P54360 →
Q70D51 — 0.976 Q70D51 →
Q4KLM6 — 0.976 Q4KLM6 →
PI4K2B Phosphatidylinositol 4-kinase type 2-beta 0.975 landscape →
Q6GX83 — 0.975 Q6GX83 →
LIPE Hormone-sensitive lipase 0.975 landscape →
Q3UHH8 — 0.975 Q3UHH8 →
Q86VZ4 — 0.975 Q86VZ4 →
Q9D3S3 — 0.975 Q9D3S3 →
Q76KP1 — 0.974 Q76KP1 →
A0PJZ3 — 0.974 A0PJZ3 →
P35054 — 0.974 P35054 →